Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rd Néphrologie operates within the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This specific matter is being reviewed by 1 distinct examiner, indicating a concentrated prosecution profile. The activity is confined to 1 distinct art unit, which suggests a specific technical focus for the company current patent applications.
The examiner KOMATSU, LI N is the busiest official for this portfolio, currently managing 1 pending office action. Because the workload is limited to 1 distinct examiner, the company immediate interactions with the patent office are located at a centralized point of review. This individual is the only examiner currently assigned to the pending matters.
For practitioners, this means the 1 pending office action is the sole focus of current prosecution efforts. The involvement of 1 distinct art unit and 1 distinct examiner allows for a focused management of the portfolio, as there are no competing deadlines or varying examiner styles to navigate. The pending action represents the entirety of the company current engagement with the Biotechnology & Pharmaceuticals examination divisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258469 | PEPTIDES FOR PREVENTING OR TREATING HEART AND BLOOD VESSEL DISEASES | KOMATSU, LI N | 71d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258469 | PEPTIDES FOR PREVENTING OR TREATING HEART AND BLOOD VESSEL DISEASES | KOMATSU, LI N | 71d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258469 | PEPTIDES FOR PREVENTING OR TREATING HEART AND BLOOD VESSEL DISEASES | KOMATSU, LI N | 1658 | §102§103 | Final Rejection | 71d | Pending | Jun 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial